Related Experiment Video
Updated: Feb 9, 2026

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice
Published on: July 23, 2017
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat
Noboru Kurinami1, Seigo Sugiyama2, Akira Yoshida1
1Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Dapagliflozin treatment significantly reduced liver fat accumulation in Japanese patients with type 2 diabetes. This was associated with decreased abdominal fat and improved liver enzymes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a global health concern.
- Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in T2DM.
- Liver fat accumulation contributes to metabolic dysfunction in T2DM.
Purpose of the Study:
- To investigate the effects of dapagliflozin on liver fat accumulation in Japanese T2DM patients.
- To compare dapagliflozin with non-SGLT2 inhibitors regarding liver fat changes.
- To explore the relationship between liver fat reduction and other metabolic parameters.
Main Methods:
- Prospective study of Japanese T2DM patients with HbA1c >7.0%.
- Patients received either dapagliflozin (5 mg/day) or non-SGLT2 inhibitors for 6 months.
- Liver fat assessed by liver-to-spleen (L/S) attenuation ratio using abdominal CT.
Main Results:
- Dapagliflozin significantly increased the L/S ratio compared to non-SGLT2 inhibitors.
- Dapagliflozin group showed significant reductions in abdominal subcutaneous fat area (SFA), visceral fat, ALT, and GGT.
- Increased L/S ratio correlated negatively with decreased SFA, ALT, and non-esterified fatty acid.
Conclusions:
- Dapagliflozin effectively reduces liver fat accumulation in T2DM patients.
- The reduction in liver fat is linked to decreased abdominal SFA.
- Dapagliflozin may offer benefits beyond glycemic control for metabolic health in T2DM.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Fats as Energy Storage Molecules
Decreasing Function
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Decreased Body Temperature

